trending Market Intelligence /marketintelligence/en/news-insights/trending/gelhMydR5xHdcnvhdWl_PQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gilead's hepatitis C virus therapy Vosevi wins approval in China

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Gilead's hepatitis C virus therapy Vosevi wins approval in China

Gilead Sciences Inc.'s hepatitis C medicine Vosevi has been approved in China.

Vosevi was approved by the China National Medical Products Administration to treat chronic hepatitis C virus infection in adults with or without liver damage who have failed prior treatment with a direct-acting antiviral therapy.

Foster City, Calif.-based Gilead said the approval was backed by data from two global phase 3 studies called Polaris-1 and Polaris-4.

About 10 million people in China are infected with hepatitis C virus, Gilead said in a Dec. 20 press release.

Vosevi — a once-daily single-tablet regimen — was approved in the U.S. and EU in 2017. The therapy is a combination of sofosbuvir, velpatasvir and voxilaprevir. For the nine months ended Sept. 30, Vosevi generated $201 million in worldwide sales, down from $319 million in the same period of 2018.